What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Tirzepatide, Placebo for type 1 diabetes, obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * Have type 1 diabetes and on insulin treatment for at least one year prior to screening * Have an HbA1c value of 7.0% to 10.5% inclusive, at screening * Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening * Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study Exclusion Criteria: * Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization. * Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization. * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have had chronic or acute pancreatitis * Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening
Study sites by state
California
- Sansum Diabetes Research Institute — Santa Barbara
- Care Access - Santa Clarita — Santa Clarita
Colorado
- University of Colorado Anschutz Medical Campus — Aurora
Georgia
- Atlanta Diabetes Associates — Atlanta
- Orita Clinical Research — Decatur
- North Georgia Clinical Research — Woodstock
Hawaii
- East-West Medical Research Institute — Honolulu
Idaho
- Rocky Mountain Clinical Research — Idaho Falls
Illinois
- Southern Illinois University School of Medicine — Springfield
Indiana
- Indiana University Health University Hospital — Indianapolis
Iowa
- Iowa Diabetes and Endocrinology Research Center — West Des Moines
Maryland
- Endocrine and Metabolic Consultants — Rockville
Minnesota
- HealthPartners Institute dba International Diabetes Center — Minneapolis
Mississippi
- SKY Integrative Medical Center/SKYCRNG — Ridgeland
Montana
- Boeson Research MSO — Missoula
Nevada
- Palm Research Center Tenaya — Las Vegas
- Palm Research Center Sunset — Las Vegas
New York
- Albany Medical College, Division of Community Endocrinology — Albany
- Research Foundation of SUNY - University of Buffalo — Buffalo
- NYC Research — New York
- SUNY Upstate Medical University — Syracuse
North Carolina
- Lucas Research, Inc. — Morehead City
Ohio
- Care Access - Lima — Lima
Oklahoma
- Alliance for Multispecialty Research, LLC — Norman
Pennsylvania
- Suburban Research Associates — West Chester
Texas
- Texas Diabetes & Endocrinology, P.A. — Austin
- Velocity Clinical Research, Dallas — Dallas
- Tekton Research, LLC. — McKinney
- Medrasa Clinical Research — Wylie
Washington
- Eastside Research Associates — Redmond
- Rainier Clinical Research Center — Renton
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)